

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except that Offer Shares may be offered, sold or delivered to QIBs in reliance on an exemption from registration under the U.S. Securities Act provided by, and in accordance with the restrictions of, Rule 144A or another exemption from the registration requirements of the U.S. Securities Act. The Offer Shares may be offered, sold or delivered outside the United States in offshore transactions in accordance with Regulation S.

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. Potential investors should read the prospectus dated 15 December 2015 (the “**Prospectus**”) issued by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered.*

*In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited or its affiliates or any person acting for it (the “**Stabilising Manager**”), on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilising or supporting the market price of the Offer Shares at a level higher than that which might otherwise prevail for a limited period which begins on the Listing Date and ends on the thirtieth day after the last day for the lodging of applications under the Hong Kong Public Offering (i.e. the period from 29 December 2015 to 17 January 2016). However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it to conduct any such stabilising action. Such stabilisation may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Such stabilisation, if commenced, will be conducted at the absolute discretion of the Stabilising Manager or its affiliates or any person acting for it and may be discontinued at any time, and must be brought to an end after the abovementioned period. The details of the intended stabilisation and how it will be regulated under the Securities and Futures Ordinance are contained in the Prospectus. Pursuant to the Over-allotment Option, the Representative on behalf of the International Purchasers have the right, exercisable at any time during the 30 day period from the last date for the lodging of applications under the Hong Kong Public Offering, to require our Company to issue and allot up to 13,519,800 additional H Shares, representing 15% of the initial Offer Shares under the Global Offering, at the same price per Offer Share under the International Offering to cover, among other things, over-allocation in the International Offering, if any. If the Over-allotment Option is exercised in full, the Offer Shares will represent approximately 22.3% of the Company’s enlarged share capital immediately following the completion of the Global Offering and the exercise of the Over-allotment Option. In the event that such Over-allotment Option is exercised, a press announcement will be made.*

Potential investors should be aware that stabilising action cannot be taken to support the price of the H Shares for longer than the stabilisation period which begins on the Listing Date and is expected to expire on Sunday, 17 January 2016, being the thirtieth day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilising action may be taken. Demand for the H Shares, and therefore the price of the H Shares, could fall. Unless otherwise defined in this announcement, terms defined in the Prospectus have the same meanings when used in this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
宜昌東陽光長江藥業股份有限公司

(A joint stock limited company incorporated in the People's Republic of China)

GLOBAL OFFERING

Number of Offer Shares in the Global Offering	: 90,132,000 H Shares (subject to the Over-allotment Option)
Number of International Offer Shares	: 81,118,800 H Shares (subject to adjustment and the Over-allotment Option)
Number of Hong Kong Offer Shares	: 9,013,200 H Shares (subject to adjustment)
Maximum offer price	: HK\$18.50 per Offer Share, plus 1% brokerage, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	: RMB1.00 per H Share
Stock code	: 1558

Sole Sponsor



Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



Joint Bookrunners and Joint Lead Managers



The Company has applied to the Listing Committee of the Hong Kong Stock Exchange for the listing of, and permission to deal in, the H Shares, including (i) the Offer Shares; (ii) any H Shares which may be issued or sold pursuant to the exercise of the Over-allotment Option; and (iii) 135,527,450 unlisted foreign shares of the Company to be converted into H Shares. Dealings in the H Shares on the Hong Kong Stock Exchange are expected to commence on 29 December 2015. In the event the Over-allotment Option is exercised, an announcement will be made by the Company which will be posted on the website of the Hong Kong Stock Exchange (www.hkexnews.hk) and on the website of the Company (www.hec-changjiang.com). The H Shares will be traded in board lots of 200 H Shares each. The Company is initially offering 81,118,800 Offer Shares (subject to adjustment and before exercise of the Over-allotment Option) under the International Offering and 9,013,200 Offer Shares for subscription by the public in Hong Kong at the Offer Price, representing 90% and 10%, respectively, of the total number of Offer Shares initially available under the Global Offering. In connection with the Global Offering, the International Purchasers will have the right, exercisable by the Representative (on behalf of the International Purchasers) at any time during the 30 day period from the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue and allot up to an aggregate of 13,519,800 additional H Shares, representing 15% of the initial Offer Shares to be offered in the Global Offering at the Offer Price under the International Offering to, among others, cover over-allocations in the International Offering, if any. Please refer to the section headed “Structure of the Global Offering” of the Prospectus for more details.

The allocation of the H Shares between the Hong Kong Public Offering and the International Offering is subject to adjustment as stated in the paragraph headed “The Hong Kong Public Offering – Reallocation” under the section in the Prospectus entitled “Structure of the Global Offering”.

Subject to the granting of the approval for listing of, and permission to deal in, the H Shares on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Hong Kong Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the H Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$18.50 and is expected to be not less than HK\$13.70 per H Share unless otherwise announced, not later than on the morning of the last day for lodging applications under the Hong Kong Public Offering.

Applications for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$18.50 per H Share, in addition to the brokerage, the SFC transaction levy and the Stock Exchange trading fee payable on each Offer Share, and will only be considered on the basis of the terms and conditions set out in the Prospectus, the **WHITE** or **YELLOW** Application Forms and the designated website (www.eipo.com.hk) for **White Form eIPO**. Please refer to the section headed “Structure of the Global Offering” of the Prospectus for more details.

Applicants who wish to be issued the Hong Kong Offer Shares in their own names should either (i) complete and sign the **WHITE** Application Form; or (ii) submit applications online through the designated website of the **White Form eIPO Service Provider** at **www.eipo.com.hk** under the **White Form eIPO** service. Applicants who wish to have the Hong Kong Offer Shares issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock account or their designated CCASS Participant's stock account should either (i) complete and sign the **YELLOW** Application Form; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Tuesday, 15 December 2015 till 12:00 noon on Friday, 18 December 2015 (or such later date as may apply as described in the section headed "How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus) from any of the following addresses of the Hong Kong Underwriters:

China International Capital Corporation Hong Kong Securities Limited

29th Floor
One International Finance Centre
1 Harbour View Street
Central
Hong Kong

ICBC International Securities Limited

37/F, ICBC Tower
3 Garden Road
Central
Hong Kong

CMB International Capital Limited

Units 1803-4
18/F Bank of America Tower
12 Harcourt Road
Central, Hong Kong

ABCI Securities Company Limited

10/F Agricultural Bank of China Tower
50 Connaught Road Central
Central
Hong Kong

CCB International Capital Limited

12/F CCB Tower
3 Connaught Road Central
Central
Hong Kong

Nomura International (Hong Kong) Limited

30/F Two International Finance Centre
8 Finance Street
Central
Hong Kong

or any of the following branches of:

(1) Bank of China (Hong Kong) Limited

District	Branch	Address
Hong Kong Island:	Central District Branch	2A Des Voeux Road Central
	Causeway Bay Branch	505 Hennessy Road, Causeway Bay, Hong Kong
Kowloon:	Yau Ma Tei Branch	471 Nathan Road, Yau Ma Tei
	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O
New Territories:	Kau Yuk Road Branch	18-24 Kau Yuk Road, Yuen Long

(2) Wing Lung Bank Limited

District	Branch	Address
Hong Kong Island:	Head Office	45 Des Voeux Road Central
Kowloon:	Mongkok Branch	B/F Wing Lung Bank Centre, 636 Nathan Road
	Tsim Sha Tsui Branch	4 Carnarvon Road
	To Kwa Wan Branch	64 To Kwa Wan Road
New Territories:	Shatin Plaza Branch	21 Shatin Centre Street

(3) Industrial and Commercial Bank of China (Asia) Limited

District	Branch	Address
Hong Kong Island:	West Point Branch	242-244 Queen's Road West, Sai Ying Pun
	Quarry Bay Branch	Shop SLG1, Sub-Lower Ground Floor, Westlands Gardens, Nos. 2-12 Westlands Road, Quarry Bay
Kowloon:	Mei Foo Branch	Shop N95A, 1/F, Mount Sterling Mall, Mei Foo Sun Chuen
New Territories:	Tsuen Wan Castle Peak Road Branch	G/F, 423-427 Castle Peak Road, Tsuen Wan
	Tai Po Branch	Shop F, G/F, Mee Fat Building, No 34-38 Tai Wing Lane, Tai Po

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Tuesday, 15 December 2015 till 12:00 noon on Friday, 18 December 2015 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker, who may have **YELLOW** Application Forms and the Prospectus available.

Your **WHITE** or **YELLOW** Application Forms can be lodged at the following times on the following dates:

Tuesday, 15 December 2015	–	9:00 a.m. to 5:00 p.m.
Wednesday, 16 December 2015	–	9:00 a.m. to 5:00 p.m.
Thursday, 17 December 2015	–	9:00 a.m. to 5:00 p.m.
Friday, 18 December 2015	–	9:00 a.m. to 12:00 noon

Applicants may apply online through the **White Form eIPO** Service Provider by submitting an application through the designated website at www.eipo.com.hk from 9:00 a.m. on Tuesday, 15 December 2015 till 11:30 a.m. on Friday, 18 December 2015 or such later date as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus (24 hours daily, except on the last application day).

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Tuesday, 15 December 2015 till 12:00 noon on Friday, 18 December 2015 (or such later date as may apply as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus). **Electronic application instructions** can be inputted by CCASS Clearing/Custodian Participants at the following times on the following dates:

Tuesday, 15 December 2015	–	9:00 a.m. to 8:30 p.m. ⁽¹⁾
Wednesday, 16 December 2015	–	8:00 a.m. to 8:30 p.m. ⁽¹⁾
Thursday, 17 December 2015	–	8:00 a.m. to 8:30 p.m. ⁽¹⁾
Friday, 18 December 2015	–	8:00 a.m. ⁽¹⁾ to 12:00 noon

Note:

- (1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants.

Please refer to the sections entitled “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

It is expected that the Offer Price will be published on Monday, 28 December 2015.

The Company expects to announce the final offer price and the results of applications in the Hong Kong Public Offering, including indication of levels of interest in the International Offering, levels in the applications of the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Monday, 28 December 2015 in the South China Morning Post (in English), the Hong Kong Economics Times (in Chinese), the website of the Hong Kong Stock Exchange (www.hkexnews.hk) and the website of the Company (www.hec-changjiang.com).

The results of allocation of the Hong Kong Public Offering and the Hong Kong Identity Card/passport/Hong Kong Business Registration numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – 11. Publication of Results” in the Prospectus.

No temporary documents of title will be issued in respect of the H Shares and no receipt will be issued for sums paid on application. H Share certificates will only become valid certificates of title at 8:00 a.m. on Tuesday, 29 December 2015 provided that the Hong Kong Public Offering has become unconditional in all respects and the right of termination described in the section entitled “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” has not been exercised. Dealings in the Shares are expected to commence at 9:00 a.m. on Tuesday, 29 December 2015. The H Shares will be traded in board lots of 200 H Shares each. The stock code of the H Shares is 1558.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hong Kong, 15 December 2015

As at the date of this announcement, the Executive Directors of the Company are JIANG Juncai, WANG Danjin and CHEN Yangui; the Non-Executive Directors are TANG Xinfa, ZHU Yingwei and MO Kit; and the Independent Non-Executive Directors are TANG Jianxin, FU Hailiang and LEE Chi Ming.

Please also refer to the published version of this announcement in the *South China Morning Post* (in English) and the *Hong Kong Economic Times* (in Chinese).